Biohacking is not a single modality but a loosely grouped category of practices united by the intention to optimise biological function through deliberate self-directed intervention. Evaluating the evidence requires treating each sub-modality separately, since the research landscapes are entirely distinct — ranging from replicated randomised trials to preclinical animal data to anecdotal reports.
This overview summarises the current state of research for each principal sub-modality, noting key methodological limitations and distinguishing between what has been demonstrated in credible trials and what remains early-stage or theoretical.
Cold Water Immersion and Cryotherapy
Cold water immersion (CWI) and whole-body cryotherapy (WBC) are among the best-studied biohacking interventions. A substantial body of RCT evidence supports their use for post-exercise recovery: CWI consistently reduces delayed-onset muscle soreness (DOMS) and perceived fatigue in athletic populations. Meta-analyses confirm this effect, though the magnitude is moderate and cooling temperature and duration affect outcomes.
Beyond recovery, cold exposure triggers robust sympathetic nervous system activation and norepinephrine release, which is mechanistically consistent with reported improvements in mood, alertness, and stress resilience. Studies on regular cold exposure have shown improvements in insulin sensitivity. The Wim Hof Method — which combines cold exposure with specific breathwork — has been the subject of a notable immunology study (Kox et al., 2014) demonstrating that trained practitioners could voluntarily influence innate immune responses, a finding that challenged established understanding and has been partially replicated.
Limitations: most trials are small and conducted in athletic populations, limiting generalisability. Optimal protocols (temperature, duration, frequency) are not standardised. There is debate about whether cold immersion after strength training may blunt hypertrophy adaptations by attenuating post-exercise inflammation.
Infrared Sauna
Much of the sauna evidence base comes from Finnish cohort studies, particularly the KIHD (Kuopio Ischaemic Heart Disease) study, which found dose-dependent associations between sauna frequency and reduced cardiovascular disease mortality, sudden cardiac death, and all-cause mortality in a large male cohort. These are observational associations, not causal proofs — confounders including fitness level and socioeconomic status are difficult to fully control.
Intervention trials show acute cardiovascular effects (blood pressure reduction, improved endothelial function) and parasympathetic nervous system activation consistent with the relaxation and recovery benefits reported by users. Infrared-specific research is thinner than traditional sauna data but shows comparable subjective recovery and autonomic benefits at lower ambient temperatures. Evidence for sauna use improving sleep quality is emerging from small studies.
Photobiomodulation (Red and Near-Infrared Light Therapy)
Photobiomodulation (PBM) has a well-characterised primary mechanism: red (630–700 nm) and near-infrared (800–1100 nm) light is absorbed by cytochrome c oxidase in mitochondria, stimulating increased ATP production and modulating reactive oxygen species and nitric oxide. This mechanistic foundation gives PBM greater biological plausibility than many wellness interventions.
Clinical evidence is strongest for wound healing and tissue repair (FDA-cleared devices exist for these indications), musculoskeletal pain, and androgenetic alopecia. Evidence for skin rejuvenation is positive but largely from industry-funded trials. The most intriguing frontier is neurological: several small trials suggest benefits for traumatic brain injury, Alzheimer's disease, and cognitive performance, but large independent RCTs are lacking.
Limitations: trial heterogeneity is significant — wavelength, power density, session duration, and target tissue vary substantially across studies, making meta-analyses difficult. Many consumer devices deliver doses below those studied in trials. Industry funding is prevalent. Optimal dosing parameters for specific indications are not established.
Breathwork
Breathwork encompasses a wide range of techniques — Wim Hof, box breathing, 4-7-8 patterns, holotropic breathing, and pranayama-derived practices. The autonomic nervous system mechanism is well-understood: controlled breathing directly modulates heart rate variability (HRV) through baroreceptor-vagal pathways, and hyperventilation patterns alter CO2/O2 balance to produce distinct physiological states.
Research evidence shows consistent acute effects on HRV, cortisol, and self-reported anxiety with slow-paced coherent breathing. The Wim Hof immunology study stands as a notable outlier in demonstrating immune modulation with a specific protocol. Evidence for longer-term clinical outcomes from regular breathwork practice is thinner, with most trials being small, short in duration, and lacking appropriate control conditions.
Peptide Therapy
Peptide therapy for optimisation purposes — as distinct from licensed peptide medicines — sits at the experimental end of the biohacking spectrum. Compounds such as BPC-157 (gastrointestinal and tissue repair), TB-500 (systemic tissue healing and recovery), and various growth hormone releasing peptides (GHRPs) have shown promising results in animal studies, with plausible mechanisms involving growth factor signalling and anti-inflammatory pathways.
Human clinical trial data is sparse and largely absent from registered, peer-reviewed sources for optimisation indications. Regulatory status varies: some peptides are unlicensed, others are research chemicals, and some (such as certain GHRPs) are controlled substances or on WADA prohibited lists. Anyone considering peptide therapy should seek qualified medical supervision, pharmaceutical-grade sourcing verification, and jurisdiction-specific regulatory guidance.
Mild Hyperbaric Oxygen Therapy (mHBOT)
Medical HBOT at pressures of 2.0–3.0 ATA with 100% oxygen has established evidence for wound healing, decompression sickness, radiation tissue injury, and carbon monoxide poisoning — these are licensed indications with substantial RCT support.
Mild hyperbaric oxygen therapy (mHBOT), typically at 1.3–1.5 ATA, is used in wellness contexts for recovery, neuroplasticity, and anti-ageing effects. A notable Israeli trial (Hachmo et al., 2020) showed telomere lengthening and reduced senescent cells after sixty mHBOT sessions — findings that generated significant interest but have not yet been independently replicated at scale. Most mHBOT optimisation evidence comes from small observational studies or single trials. It remains an early-stage intervention for optimisation uses and should only be administered by trained practitioners.
Summary: Where the Evidence Stands
Across biohacking sub-modalities, the evidence gradient runs roughly from cold exposure and infrared sauna (moderate, replicated evidence for specific outcomes) through photobiomodulation (emerging evidence with good mechanistic support) to breathwork (strong mechanism, fewer clinical trials) to peptide therapy and mHBOT (largely experimental for optimisation purposes). Informed engagement means calibrating expectations to where each practice actually sits on that spectrum rather than treating the category as uniformly evidenced — or uniformly dismissing it.
